Classifica tra le azioni
#41229
GENinCode Plc specializes in the creation and commercialization of advanced... GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
Prezzo delle azioni
$0.01206398
Capitalizzazione di mercato
$33.74K
Variazione (1 giorno)
-1.49%
Variazione (1 anno)
-40.77%
Scambia GENinCode plc (GENI)
Ricavi di GENinCode plc (GENI)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di GENinCode plc, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per GENinCode plc da 2026 a 2026
Ricavi alla fine di ogni anno
| Anno |
Ricavi |
Cambia |
|
Non abbastanza dati per le date fornite. |
Ricavi di aziende simili o concorrenti
| Azienda |
Ricavi |
Differenza nei ricavi |
Il paese |
|
|
$46.34B |
-
|
US
|
|
|
$25.11B |
-
|
US
|
|
|
- |
-
|
CN
|
|
|
$4.55B |
-
|
US
|
|
|
$2.71B |
-
|
US
|
